DeepMed Research

Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: Private, Subsidiary

Established: 2004-07-08

Employees: -

Market Cap: -

Website: http://www.pinganzhengxing.com

Clinical Trials

Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03

Phase 3

Conditions: IMRT With or Without Concurrent Chemotherapy for Esophageal Cancer

Interventions: Radiation: SIB-IMRT
Drug: Paclitaxel
Drug: Platinum-Based Drug
Other: Involved Field Irradiation (IFI)

First Posted Date: 2017-11-01

Last Posted Date: 2019-01-02

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 2

Registration Number: NCT03328234

Locations: 🇨🇳
Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China

Hypofractionated Radiation Therapy With Concomitant Boost in Treating Women After Breast Conserving Surgery

Not Applicable

Completed

Conditions: Breast Cancer Female

Interventions: Radiation: Radiation therapy

First Posted Date: 2017-10-25

Last Posted Date: 2019-01-31

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 90

Registration Number: NCT03320421

Locations: 🇨🇳
National Cancer Center/Cancer Hosptial, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02

Phase 3

Conditions: Esophageal Neoplasms

Interventions: Radiation: SIB-IMRT
Drug: Paclitaxel
Drug: Platinum-Based Drug

First Posted Date: 2017-10-12

Last Posted Date: 2019-01-02

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 164

Registration Number: NCT03308552

Locations: 🇨🇳
Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, Beijing, China

Definitive (Chemo)Radiotherapy for Patients With Esophageal Cancer - 3JECROG R-01

Completed

Conditions: Esophagus Cancer
Radiotherapy Side Effect
Chemoradiation
Chemotherapy Effect

First Posted Date: 2017-10-02

Last Posted Date: 2019-01-02

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 2762

Registration Number: NCT03298204

Locations: 🇨🇳
Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China

The Phase IVd of Inactivated Enterovirus 71 Vaccine

Phase 4

Conditions: Hand, Foot and Mouth Disease (HFMD)

Interventions: Biological: two measles attenuated live vaccine
Biological: live attenuated Japanese encephalitis vaccine
Biological: EV71 and attenuated Japanese encephalitis vaccine
Biological: EV71 and two measles attenuated live vaccine
Biological: EV71 vaccine

First Posted Date: 2017-09-28

Last Posted Date: 2017-09-28

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 1220

Registration Number: NCT03296410

Locations: 🇨🇳
Guangdong Province Center for Diseases Control and Prevention, Guangzhou, Guangdong, China

Comparative Study of Different Neoadjuvant Therapies Before Radical Hysterectomy in Stage Ib2-IIa2 Cervical Cancer

Not Applicable

Completed

Conditions: Cervical Cancer

Interventions: Radiation: combination group
Drug: chemotherapy group

First Posted Date: 2017-08-09

Last Posted Date: 2017-08-09

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 120

Registration Number: NCT03243825

Locations: 🇨🇳
Cancer Hospital, Chinese Acadamy of Medical Sceinces, Beijing, China

The Phase IVc of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell)

Phase 4

Conditions: Hand, Foot and Mouth Disease (HFMD)

Interventions: Biological: Inactivated EV71 vaccine (human diploid cell, KMB-17)

First Posted Date: 2017-08-07

Last Posted Date: 2017-09-06

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 800

Registration Number: NCT03240744

Locations: 🇨🇳
Hubei Province Center for Diseases Control and Prevention, Wuhan, Hubei, China

How do Super Lean Subjects Keep Resistant to Body Weight Gain?

Recruiting

Conditions: Health Behavior
Thinness
Genetics

Interventions: Behavioral: Superlean

First Posted Date: 2017-07-18

Last Posted Date: 2022-07-21

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 300

Registration Number: NCT03221322

Locations: 🇨🇳
Institute of Genetics and Developmental Biology, Beijing, China

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor

Phase 2

Conditions: Extrapancreatic Neuroendocrine Tumor

Interventions: Drug: Tegafur
Drug: Temozolomide
Drug: Thalidomide

First Posted Date: 2017-06-29

Last Posted Date: 2017-06-29

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 60

Registration Number: NCT03204032

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor

Phase 2

Conditions: Pancreatic Neuroendocrine Tumor

Interventions: Drug: Tegafur and Temozolomide combined with Thalidomide
Drug: Tegafur and Temozolomide

First Posted Date: 2017-06-29

Last Posted Date: 2017-06-29

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 60

Registration Number: NCT03204019

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy